Dr. Uhl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4940 Eastern Ave
Dept Of Neurology
Baltimore, MD 21224Phone+1 410-550-2843Fax+1 410-550-1535
Education & Training
Johns Hopkins UniversityResidency, Neurology, 1980 - 1983
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1979 - 1980- Johns Hopkins University School of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 1979 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Investigator Alumnus Howard Hughes Medical Institute, 1983
Clinical Trials
- Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics Start of enrollment: 2004 Dec 22
- The Genetic Basis for Vulnerability to Substance Abuse Start of enrollment: 1992 Aug 01
- fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia Start of enrollment: 2005 Feb 08
Publications & Presentations
PubMed
- 347 citationsCloning of the gamma-aminobutyric acid (GABA) rho 1 cDNA: a GABA receptor subunit highly expressed in the retina.Garry R. Cutting, Lili Lu, Bruce F. O'Hara, Laura Kasch, C Montrose-Rafizadeh
Proceedings of the National Academy of Sciences of the United States of America. 1991-04-01 - 194 citationsmu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity.Christopher K. Surratt, Peter S. Johnson, Akiyoshi Moriwaki, Brian K. Seidleck, Carrie J. Blaschak
The Journal of Biological Chemistry. 1994-08-12 - 15 citationsMulti-ancestry genome-wide association study of major depression aids locus discovery, fine mapping, gene prioritization and causal inference.Xiangrui Meng, Georgina Navoly, Olga Giannakopoulou, Daniel F Levey, Dora Koller
Nature Genetics. 2024-02-01
Journal Articles
- Cocaine Reward Is Reduced by Decreased Expression of Receptor-Type Protein Tyrosine Phosphatase D (PTPRD) and by a Novel PTPRD AntagonistGeorge Uhl, MD, Proceedings of the National Academy of Sciences
Grant Support
- Understanding Addiction Vulnerability GenesNational Institute On Drug Abuse2009–2011
- Molecular Genetic Bases For Quit SuccessNational Institute On Drug Abuse2009–2011
- Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: MiceNational Institute On Drug Abuse2009–2011
- Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: HumansNational Institute On Drug Abuse2009–2011
- Molecular Genetic Bases For Quit SuccessNational Institute On Drug Abuse2007–2008
- Understanding Addiction Vulnerability GenesNational Institute On Drug Abuse2006–2008
- Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: MiceNational Institute On Drug Abuse1998–2008
- Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: HumansNational Institute On Drug Abuse1998–2008
- Dopamine Transporter--Structure/Function Studies Of Transporter And PromotersNational Institute On Drug Abuse2007
- Synaptic Vesicular Monamine TransporterNational Institute On Drug Abuse2000–2007
- MU Opiate ReceptorsNational Institute On Drug Abuse2000–2007
- Genetic Approaches To Characterizing Drug Responses AndNational Institute On Drug Abuse2002–2006
- Dopaminergic GenesNational Institute On Drug Abuse2002–2006
- Dopamine Transporter--Structure/Function Studies Of TranNational Institute On Drug Abuse2002–2006
- Genes Regulated By Abused DrugsNational Institute On Drug Abuse1997–2006
- Genetic Approaches To Characterizing Drug ResponsesNational Institute On Drug Abuse2005
- Dopamine Transporter--Structure/Function StudiesNational Institute On Drug Abuse2005
- Genetic Approaches To Characterizing Drug ResponsesNational Institute On Drug Abuse2004–2005
- Dopamine Transporter RegulationNational Institute On Drug Abuse2000–2005
- Synaptic Vesicular Monoamine TransporterNational Institute On Drug Abuse2004
- Dopamine Transporter-Human &Mouse Genes, Dopaminergic Disorders &Knockout MiceNational Institute On Drug Abuse1999–2000
- Dopamine Transporter--Structure/Function Studies Of Transporter And LigandsNational Institute On Drug Abuse1996–2000
- Mouse Synaptic Vesicular Monamine TransporterNational Institute On Drug Abuse1998–1999
- MU Opiate Receptors--Structure/Function And PhosphorylationNational Institute On Drug Abuse1997–1999
- Dopamine Transporter And Vesicular Monoamine TransporterNational Institute On Drug Abuse1997–1999
- Dopamine Transporter-Human &Amp;Mouse Genes, Dopaminergic Disorders &Amp;KnockoNational Institute On Drug Abuse1998
- Genetic Approaches To Characterizing Drug Responses And VulnerabilitiesNational Institute On Drug Abuse1997
- Dopamine Transporter--Human &Mouse Genes, Dopaminergic Disorders &Knockout MiceNational Institute On Drug Abuse1997
- Genetic Approaches To Characterizing Drug Responses And VulnerabilitiesNational Institute On Drug Abuse1996–1997
- Genes Regulated By Abused Drugs In Brain--Genes Involved In Neural SignalingNational Institute On Drug Abuse1996
- Dopamine Transporter--Cellular And Subcellular LocalizationNational Institute On Drug Abuse1996
- Dopamine Transporter I--Regulation By PhosphorylationNational Institute On Drug Abuse1996
- Dopamine Transporter-- Cellular And Subcellular LocalizationsNational Institute On Drug Abuse1995
- Neuroleptics/Dopamine-Co-Localized Peptide GenesNational Institute Of Mental Health1988–1990
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
